STAR0602

Clinical Trials Overview

2 trials found
About STAR0602

Descripción clínica en INGLÉS: indicaciones en CCR, eficacia general, contexto de uso (3-4 frases)

Category Other Medications
Mechanism Mecanismo de acción detallado en INGLÉS (2-3 frases, técnico pero claro)
2
Total Trials
2
Recruiting
0
Active
0
Completed
415
Total Enrollment
4
Countries
Active sites for STAR0602
Recruiting sites 4 countries
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT06827613 Phase 1 Recruiting 50 patients
Start: Mar 2025
End: Jan 2028
INTERVENTIONAL
Medications: STAR0602
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants...
United States, Canada
View Details ClinicalTrials.gov Am I eligible?
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626 Phase 1 Recruiting 365 patients
Start: Jan 2023
End: Oct 2026
INTERVENTIONAL
Medications: STAR0602
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
United States, Canada, France, Spain
View Details ClinicalTrials.gov Am I eligible?
Back to Drug Glossary View All Trials Filter Recruiting Trials